Nasdaq · Biotech stocks database
HCM — HUTCHMED (China) Limited ☆
HCM (HUTCHMED (China) Limited) stock: $15.16, $2.64B market cap, $1.37B cash, $1.28B EV, $2.72B fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Overview
Catalysts
Assets
Pipeline
Trials
Holders
News
What they do
We are a global commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of patients with cancer and immunological diseases. Our company started in China in 2000 and has since developed fully integrated capabilities and expanded oncology and immunology drug development operations globally.
Source: 20-F FY2025 via SEC EDGAR
Enterprise value
$1,277.7M
Balance sheet
Cash $1,367.2M Debt $0.0M Net cash $1,367.2M Enterprise value $1,277.7M Basic shares 174.5M shares Fully diluted shares 179.6M shares Fully diluted market cap $2,722.7M Cash per share $7.84 Quarterly burn $17.4M Cash runway 78.6 quarters
Cash figures as of 2025-12-31. Database snapshot: 2026-11-07.
Share structure
Cap table as of 2025-12-31.
Price history Loading HCM daily closes…
Loading price history…
Next catalyst HMPL-760 · Nov 12 - Dec 24 in 5d · Phase 1 · Healthy ParticipantsAll upcoming catalysts (+10 more) →
Recently reported Savolitinib Phase 3 Positive · 2026-10-26
SANOVO · non-small cell lung cancer
Savolitinib Phase 3 Positive · 2026-10-25
SAFFRON · non-small cell lung cancer
savolitinib + osimertinib Positive · 2026-08-31
Upcoming catalysts Expected Drug Phase Indication Mgmt guide Nov 12 - Dec 24 in 5d HMPL-760 Phase 1 Healthy Participants — Jan 12 - Feb 23 in 9 wks HMPL-306 Phase 1 Gliomas Harboring IDH1 and/or IDH2 Mutations — Nov 19 - Dec 31 in 13 mo HMPL-506 Phase 1 Hematological Malignancies — Jun 11 - Jul 23 in 19 mo HMPL-760 Phase 3 Relapsed/Refractory Diffuse Large B-Cell Lymphoma — Jul 12 - Aug 23 in 20 mo Nab-paclitaxel Plus Gemcitabine Phase 3 Metastatic Pancreatic Cancer — Aug 7 - Sep 18 in 21 mo HMPL-A830 Phase 2 Solid Tumor, Adult — Aug 11 - Sep 22 in 21 mo HMPL-453 Phase 3 Advanced Intrahepatic Cholangiocarcinoma; Solid Tumor, Adult — Jan 11 - Feb 22 in 27 mo HMPL-A251 Phase 2 Solid Tumors, Adult — Feb 11 - Mar 25 in 28 mo HMPL-306 Regimen Phase 3 Acute Myeloid Leukemia — Feb 11 - Mar 25 in 28 mo HMPL-A580 Phase 2 Solid Tumors, Adult — Feb 19 - Apr 2 in 28 mo fruquintinib Phase 3 Advanced Endometrial Cancer —
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Asset data not yet available for this company.
No lead program on file for this company.
Active clinical trials Trial Phase Status Role Sponsor BP Condition(s) Mgmt guide NCT07409428 Phase 3 Recruiting Sponsor HCM — Relapsed/Refractory Diffuse Large B-Cell Lymphoma — NCT05009836 Phase 3 Active, not recruiting Sponsor HCM — Non-small Cell Lung Cancer October 25, 2026 October 26, 2026 NCT06361888 Phase 3 Recruiting Sponsor HCM — Metastatic Pancreatic Cancer — NCT04353375 Phase 3 Recruiting Sponsor HCM — Advanced Intrahepatic Cholangiocarcinoma; Solid Tumor, Adult — NCT06387069 Phase 3 Recruiting Sponsor HCM — Acute Myeloid Leukemia — NCT06584032 Phase 3 Recruiting Sponsor HCM — Advanced Endometrial Cancer — NCT05522231 Phase 3 Active, not recruiting Sponsor HCM — Advanced Renal Cell Carcinoma — NCT05535933 Phase 3 Active, not recruiting Sponsor HCM — Warm Antibody Autoimmune Hemolytic Anemia — NCT07718581 Phase 2 Not yet recruiting Sponsor HCM — Solid Tumor, Adult — NCT07228247 Phase 2 Recruiting Sponsor HCM — Solid Tumors, Adult — NCT07396584 Phase 2 Recruiting Sponsor HCM — Solid Tumors, Adult — NCT06601504 Phase 2 Active, not recruiting Sponsor HCM — Relapsed/Refractory Diffuse Large B-Cell Lymphoma —
Sponsor-matched active trials from ClinicalTrials.gov (15 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
View all 15 active trials for Hutchmed on ClinicalTrials.gov
Specialist fund holders Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Fully Diluted · Free biotech stocks database. Figures are sourced from SEC filings and company disclosures; not investment advice.